Daily non-political popular news in brief.
Radiation after surgery doubles survival time for some lung cancer patients
11-06-2006 · EurekAlert!Patients with lung cancer that has spread to mediastinal lymph nodes -- located between the chest, breastbone and spine -- who receive radiation after surgery and chemotherapy live twice as long as patients who do not receive radiation after surgery, according to a study presented at the plenary session November 6, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.
Read more »
Keywords: radiation, surgery, doubles, survival, time, lung, cancer, patients, double, patient
« Previous | Next »
Similar news on "Radiation after surgery doubles survival time for some lung cancer patients":
- Radiation preferred over surgery for patients with some stages of lung cancer
03-20-2007 · EurekAlert!
After an initial chemotherapy treatment, radiation may be a better choice than surgery for patients with stage IIIA non-small-cell lung cancer, according to a randomized controlled trial published in the March 21 Journal of the National Cancer Institute. The authors suggest that a combination of chemotherapy and radiation should be the preferred treatment option for these patients.
Similar news · Read more »
- Minimally invasive lung cancer surgery can improve chemotherapy outcomes
04-09-2007 · EurekAlert!
Patients who undergo a minimally invasive lung cancer surgery called thoracoscopic lobectomy may derive more benefit from the chemotherapy that follows, according to Duke University Medical Center researchers. These patients also have shorter hospital stays and accelerated recovery time compared with patients who have their tumors removed using the traditional surgical approach that involves opening the chest.
Similar news · Read more »
- Jefferson researchers show chemotherapy and radiation together extend lung cancer patients' lives
11-09-2007 · EurekAlert!
Chemotherapy given at the same time as radiation therapy can help patients with a certain type of lung cancer live nearly 50 percent longer than they might have otherwise if the same treatment was given differently, according to an international team’s analysis of several trial results.
Similar news · Read more »
- Report calls for using heated chemotherapy after colon cancer surgery to optimize patient survival
11-03-2006 · EurekAlert!
There is new hope for some of the most seriously ill colon cancer patients today, following the release of a consensus statement by 72 leading oncology surgeons from 14 countries, including the United States. The Peritoneal Surface Malignancy Group (PSMG) has concluded that surgery, followed by heated chemotherapy delivered through the lower abdomen of the patient before leaving the operating room, may significantly increase the life expectancy for patients with Stage IV colorectal cancer.
Similar news · Read more »
- New breakthrough treatment for spinal cancer patients at Mount Sinai
05-16-2007 · EurekAlert!
The Mount Sinai Medical Center is the only hospital in New York City using the Novalis Shaped Beam Surgery System on spinal cancer. Novalis is the most advanced Stereotactic Radiosurgery technology available to treat cancer tumors in the spine. Doctors at Mount Sinai are at the forefront of this medical breakthrough in neurosurgery and radiation oncology, using this technology to control deadly and complicated tumors from the spine for the first time ever.
Similar news · Read more »
- New cancer treatment adds to survival rates in lung cancer patients
06-28-2007 · EurekAlert!
Patients with inoperable non-small cell lung cancer who receive an initial high dose of chemotherapy before their treatment begins can expect an increase in overall survival, according to a study in the July 1 issue of the International Journal of Radiation Oncology, Biology, Physics, the official journal of ASTRO.
Similar news · Read more »
- More than 6 months of hormone therapy doesn't help prostate cancer patients live longer
11-05-2006 · EurekAlert!
Prostate cancer patients treated with either radiation or surgery who use hormone therapy for longer than six months do not survive any longer than patients who use the treatment for a shorter amount of time, according to a study presented November 5, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.
Similar news · Read more »
- Rhode Island Hospital study confirms RF ablation effective for treating inoperable lung cancer
03-27-2007 · EurekAlert!
The overall results of a study of 153 patients with inoperable lung cancer show RF ablation to be safe and linked it with promising long-term survival and local tumor progression outcomes when compared to the older treatment method of external beam radiation (EBT). The study appears in the April issue of the journal Radiology.
Similar news · Read more »
- Surgeons say minimally invasive lung surgery should be standard care
06-29-2007 · EurekAlert!
Major US academic medical centers can successfully -- and safely -- integrate minimally invasive lung surgery into their training programs with a standardized, step-by-step plan, according to University of Cincinnati thoracic surgeons. It's estimated that only about 10 percent of all lung cancer operations nationwide are done with minimally invasive techniques, but more than half the patients who need the surgery would qualify for the less invasive procedure, which results in faster recovery time and less pain for patients.
Similar news · Read more »
- Skin rash actually signifies better outcomes for pancreatic and lung cancer patients
07-03-2007 · EurekAlert!
The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug’s developer, OSI Pharmaceuticals, Inc. This is not the first time that rash has been associated with a survival advantage with EGFR inhibitors -- a class of drugs which includes erlotinib, cetuximab, panitumumab and others designed to block overproduction of the epidermal growth factor receptor -- but it is the most detailed analysis to date.
Similar news · Read more »
